criteria for APS and do not have another indication for the drug (such as SLE), we conditionally recommend against treating with prophylactic HCQ. As with any unproven treatment, this therapy may be considered in specific circumstances, depending on a patient's values and preferences and after a discussion about risks and benefits. Anti-Ro/SSA and/or anti-La/SSB antibodies in pregnancy. Neonatal lupus erythematosus (NLE) describes several fetal and infant manifestations caused by or associated with maternal anti-Ro/SSA (commonly) and anti-La/SSB autoantibodies. While isolated anti-La/SSB rarely imposes risk, when combined with anti-Ro/SSA, La/SSB antibodies may increase fetal risk Complete (third-degree) heart block (CHB) occurs in ~2% of pregnancies of women with anti-Ro/SSA and/or anti-La/SSB antibodies who have not had a prior infant with NLE, and in 13-18% of pregnancies of women with a prior infant who had either cutaneous or cardiac NLE http://onlin elibr ary.